Analytical testing demonstrated that NurExone’s exosomes produced from human bone marrow–derived mesenchymal stem cells (“MSC”) exhibit significantly higher CD73-associated biological activity compared with a commercially available MSC exosome control.
Analytical testing demonstrated that NurExone’s exosomes produced from human bone marrow–derived mesenchymal stem cells (“MSC”) exhibit significantly higher CD73-associated biological activity compared with a commercially available MSC exosome control.